USA - NASDAQ:LAB - US34385P1084 - Common Stock
The current stock price of LAB is 1.25 USD. In the past month the price decreased by -6.98%. In the past year, price decreased by -24.05%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 26.03 | 220.15B | ||
| DHR | DANAHER CORP | 28.85 | 159.26B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 163.31 | 49.55B | ||
| A | AGILENT TECHNOLOGIES INC | 27.12 | 41.91B | ||
| IQV | IQVIA HOLDINGS INC | 19.22 | 37.99B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 33.89 | 29.21B | ||
| WAT | WATERS CORP | 30.23 | 22.85B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 37.09 | 18.86B | ||
| ILMN | ILLUMINA INC | 27.83 | 18.65B | ||
| MEDP | MEDPACE HOLDINGS INC | 41.87 | 16.82B | ||
| TEM | TEMPUS AI INC | N/A | 12.07B | ||
| RVTY | REVVITY INC | 19.29 | 10.73B |
Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. The company is headquartered in South San Francisco, California and currently employs 818 full-time employees. The company went IPO on 2011-02-10. The firm's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The firm works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. The company offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.
STANDARD BIOTOOLS INC
2 Tower Place, Suite 2000
South San Francisco CALIFORNIA US
Employees: 818
Phone: 16502666000
Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. The company is headquartered in South San Francisco, California and currently employs 818 full-time employees. The company went IPO on 2011-02-10. The firm's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The firm works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. The company offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.
The current stock price of LAB is 1.25 USD. The price increased by 4.17% in the last trading session.
LAB does not pay a dividend.
LAB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
LAB stock is listed on the Nasdaq exchange.
7 analysts have analysed LAB and the average price target is 1.81 USD. This implies a price increase of 44.84% is expected in the next year compared to the current price of 1.25.
The outstanding short interest for STANDARD BIOTOOLS INC (LAB) is 3.18% of its float.
ChartMill assigns a fundamental rating of 2 / 10 to LAB. LAB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months LAB reported a non-GAAP Earnings per Share(EPS) of -0.34. The EPS increased by 52.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.77% | ||
| ROE | -32.09% | ||
| Debt/Equity | 0 |
7 analysts have analysed LAB and the average price target is 1.81 USD. This implies a price increase of 44.84% is expected in the next year compared to the current price of 1.25.
For the next year, analysts expect an EPS growth of 59.6% and a revenue growth -49.56% for LAB